Toll-like receptor signaling in HIV-1 infection: A potential target for therapy?

Expert Review of Anti-Infective Therapy

Volumn 5, Issue 3, 2007, Pages 323-326

  Meier, Angela ^a   Altfeld, Marcus ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; IMMUNOMODULATING AGENT; ISATORIBINE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 7 AGONIST; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 8 AGONIST; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; TOLL LIKE RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADAPTIVE IMMUNITY; ANTIVIRAL ACTIVITY; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONDYLOMA; DISEASE ACTIVITY; DISEASE COURSE; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG SYNTHESIS; EDITORIAL; GENE MUTATION; GENETIC CODE; GRAM NEGATIVE INFECTION; HERPES SIMPLEX; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOPATHOGENESIS; IMMUNOSTIMULATION; NONHUMAN; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT; VIRUS REACTIVATION; VIRUS REPLICATION; VIRUS STRAIN; BIOLOGICAL MODEL; DRUG POTENTIATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METABOLISM; REVIEW;

ANTI-HIV AGENTS; HIV INFECTIONS; HIV-1; HUMANS; MODELS, IMMUNOLOGICAL; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 34447284531     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.5.3.323     Document Type: Editorial

References (54)

1. Fahey JL, Taylor JM, Detels R et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N. Engl. J. Med. 322(3), 166-172 (1990).
2. + T cells. Nature 417(6884), 95-98 (2002).
3. Silvestri G, Sodora DL, Koup RA et al. Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. Immunity 18(3), 441-452 (2002).
4. Silvestri G, Fedanov A, Germon S et al. Divergent host responses during primary simian immunodeficiency virus SIVsm infection of natural sooty mangabey and nonnatural rhesus macaque hosts. J. Virol. 79(7), 4043-4054 (2005).
5. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu. Pev. Immunol. 21, 335-376 (2003).
6. Cook DN, Pisetsky DS, Schwartz DA. Toll-like receptors in the pathogenesis of human disease. Nat. Immunol. 5(10), 975-979 (2004).
7. Takeda K, Akira S. TLR signaling pathways. Semin. Immunol. 16(1), 3-9 (2004).
8. Isogawa M, Robek MD, Furuichi Y, Chisari FV. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J. Virol. 79(11), 7269-7272 (2005).
9. Tabeta K, Georgel P, Janssen E. Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. Proc. Natl Acad. Sci. USA 101(10), 3516-3521 (2004).
10. Zhou S, Kurt-Jones EA, Fitzgerald KA et al. Role of MyD88 in route-dependent susceptibility to vesicular stomatitis virus infection. J. Immunol. 178(8), 5173-5181 (2007).
11. Suzuki N, Suzuki S, Duncan GS et al. Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4. Nature 416(6882), 750-756 (2002).
12. Mansur DS, Kroon EG, Nogueira ML et al. Lethal encephalitis in myeloid differentiation factor 88-deficient mice infected with herpes simplex virus 1. Am. J. Pathol. 166(5), 1419-1426 (2005).
13. Kurt-Jones EA, Popova L, Kwinn L et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat. Immunol. 1(5), 398-401 (2000).
14. Kash JC, Muhlberger E, Carter V et al. Global suppression of the host antiviral response by Ebola- and Marburg viruses: increased antagonism of the type I interferon response is associated with enhanced virulence. J. Virol. 80(6), 3009-3020 (2006).
15. Stack J, Haga IR, Schroder M et al. Vaccinia virus protein A46R targets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulence. J. Exp. Med. 201(6), 1007-1018 (2005).
16. Hahm B, Arbour N, Oldstone MB. Measles virus interacts with human SLAM receptor on dendritic cells to cause immunosuppression. Virology 323(2), 292-302 (2004).
17. Hahm B, Cho JH, Oldstone MB. Measles virus-dendritic cell interaction via SLAM inhibits innate immunity: selective signaling through TLR4 but not other TLRs mediates suppression of IL-12 synthesis. Virology 358(2), 251-257 (2007).
18. Ashkar AA, Bauer S, Mitchell WJ, Vieira J, Rosenthal KL. Local delivery of CpG oligodeoxynucleotides induces rapid changes in the genital mucosa and inhibits replication, but not entry, of herpes simplex virus type 2. J. Virol. 77(16), 8948-8956 (2003).
19. Herbst-Kralovetz MM, Pyles RB. Quantification of poly(I:C)-mediated protection against genital herpes simplex virus type 2 infection. J. Virol. 80(20), 9988-9997 (2006).
20. Horsmans Y, Berg T, Desager JP et al. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology 42(3), 724-731 (2005).
21. Wu CC, Hayashi T, Takabayashi K et al. Immunotherapeutic activity of a conjugate of a Toll-like receptor 7 ligand. Proc. Natl Acad. Sci. USA 104(10), 3990-3995 (2007).
22. Mark KE, Corey L, Meng TC et al. Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial. J. Infect. Dis. 195(9), 1324-1331 (2007).
23. Syed TA, Hadi SM, Qureshi ZA, Ali SM, Kwah MS. Treatment of external genital warts in men with imiquimod 2% in cream. A placebo-controlled, double-blind study. J. Infect. 41(2), 148-151 (2000).
24. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272(5265), 1167-1170 (1996).
25. Brenchley JM, Price DA, Schacker TW et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12(12), 1365-1371 (2006).
26. + T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J. Exp. Med. 200(6), 749-759 (2004).
27. + T lymphocytes from effector sites in the gastrointestinal tract. J. Exp. Med. 200(6), 761-770 (2004).
28. Haynes BF. Gut microbes out of control in HIV infection. Nat. Med. 12(12), 1351-1352 (2006).
29. Libois A, Lopez A, Garcia F et al. Dynamics of T cells subsets and lymphoproliferative responses during structured treatment interruption cycles and after definitive interruption of HAART in early chronic HIV type-1-infected patients. AIDS Res. Hum. Retroviruses 22(7), 657-666 (2006).
30. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303(5663), 1529-1531 (2004).
31. Heil F, Hemmi H, Hochrein H et al. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 303(5663), 1526-1529 (2004).
32. Meier A, Alter G, Frahm N et al. MyD88-dependent Immune Activation mediated by HIV-1-encoded TLR Ligands. J. Virol. DOI: 10.1128/ JVI.00421-07 (2007).
33. Beignon AS, McKenna K, Skoberne M et al. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor- viral RNA interactions. J. Clin. Invest. 115(11), 3265-3275 (2005).
34. Barrat FJ, Meeker T, Gregorio J et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J. Exp. Med. 202(8), 1131-1139 (2005).
35. Martin LN, Murphey-Corb M, Mack P et al. Cyclosporin A modulation of early virologic and immunologic events during primary simian immunodeficiency virus infection in rhesus monkeys. J. Infect. Dis. 176(2), 374-383 (1997).
36. Rizzardi GP, Harari A, Capiluppi B et al. Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. J. Clin. Invest. 109(5), 681-688 (2002).
37. Herbst-Kralovetz MM, Pyles RB. Quantification of poly(I:C)-mediated protection against genital herpes simplex virus type 2 infection. J. Virol. 80(20), 9988-9997 (2006).
38. Horsmans Y, Berg T, Desager JP et al. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology 42(3), 724-731 (2005).
39. Wu CC, Hayashi T, Takabayashi K et al. Immunotherapeutic activity of a conjugate of a Toll-like receptor 7 ligand. Proc. Natl Acad. Sci. USA 104(10), 3990-3995 (2007).
40. Mark KE, Corey L, Meng TC et al. Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial. J. Infect. Dis. 195(9), 1324-1331 (2007).
41. Syed TA, Hadi SM, Qureshi ZA, Ali SM, Kwah MS. Treatment of external genital warts in men with imiquimod 2% in cream. A placebo-controlled, double-blind study. J. Infect. 41(2), 148-151 (2000).
42. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272(5265), 1167-1170 (1996).
43. Brenchley JM, Price DA, Schacker TW et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12(12), 1365-1371 (2006).
44. + T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J. Exp. Med. 200(6), 749-759 (2004).
45. + T lymphocytes from effector sites in the gastrointestinal tract. J. Exp. Med. 200(6), 761-770 (2004).
46. Haynes BF. Gut microbes out of control in HIV infection. Nat. Med. 12(12), 1351-1352 (2006).
47. Libois A, Lopez A, Garcia F et al. Dynamics of T cells subsets and lymphoproliferative responses during structured treatment interruption cycles and after definitive interruption of HAART in early chronic HIV type-1-infected patients. AIDS Res. Hum. Retroviruses 22(7), 657-666 (2006).
48. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303(5663), 1529-1531 (2004).
49. Heil F, Hemmi H, Hochrein H et al. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 303(5663), 1526-1529 (2004).
50. Meier A, Alter G, Frahm N et al. MyD88-dependent Immune Activation mediated by HIV-1-encoded TLR Ligands. J. Virol. DOI: 10.1128/ JVI.00421-07 (2007).
51. Beignon AS, McKenna K, Skoberne M et al. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor- viral RNA interactions. J. Clin. Invest. 115(11), 3265-3275 (2005).
52. Barrat FJ, Meeker T, Gregorio J et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J. Exp. Med. 202(8), 1131-1139 (2005).
53. Martin LN, Murphey-Corb M, Mack P et al. Cyclosporin A modulation of early virologic and immunologic events during primary simian immunodeficiency virus infection in rhesus monkeys. J. Infect. Dis. 176(2), 374-383 (1997).
54. Rizzardi GP, Harari A, Capiluppi B et al. Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. J. Clin. Invest. 109(5), 681-688 (2002).